Balance Sheet Cizzle Biotechnology Holdings Plc
Equities
PSL
GB00BNG2VN02
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.550 GBX | +10.71% |
|
0.00% | - |
| 05/11 | Cizzle Biotechnology Raises Funds via Convertible Loan Note Issue | MT |
| 05/11 | Cizzle Biotechnology announces LOI with leading UK clinical diagnostic group | RE |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash And Equivalents | 7T | 9L | 5L | 1L | 4L | |||||
Trading Asset Securities, Total | - | - | - | 14.13L | 22T | |||||
Total Cash And Short Term Investments | 7T | 9L | 5L | 15.57L | 4L | |||||
Other Receivables | - | 51T | 95T | 1L | 76T | |||||
Total Receivables | - | 51T | 95T | 1L | 76T | |||||
Inventory | - | - | - | - | 2T | |||||
Prepaid Expenses | 3T | 29T | 12T | 27T | 27T | |||||
Other Current Assets, Total | - | - | 1L | - | - | |||||
Total Current Assets | 10T | 10L | 7L | 16.93L | 5L | |||||
Gross Property Plant And Equipment | - | - | - | - | - | |||||
Accumulated Depreciation | - | - | - | - | - | |||||
Net Property Plant And Equipment | - | - | - | - | - | |||||
Long-term Investments | - | - | - | - | - | |||||
Other Intangibles, Total | - | 2L | 20.8L | - | - | |||||
Total Assets | 10T | 11.55L | 27.85L | 16.93L | 5L | |||||
Liabilities | ||||||||||
Accounts Payable, Total | 2T | 1L | 41T | 92T | 13T | |||||
Accrued Expenses, Total | 6T | 1L | 1L | 94T | 4L | |||||
Short-term Borrowings | 10T | - | - | - | - | |||||
Unearned Revenue Current, Total | - | - | - | - | - | |||||
Total Current Liabilities | 18T | 2L | 1L | 2L | 4L | |||||
Unearned Revenue Non Current | - | - | - | - | - | |||||
Total Liabilities | 18T | 2L | 1L | 2L | 4L | |||||
Common Stock, Total | 3T | 34.93L | 35.02L | 35.04L | 35.07L | |||||
Additional Paid In Capital | 15.85L | 3.26Cr | 3.49Cr | 3.53Cr | 3.59Cr | |||||
Retained Earnings | -15.96L | -55.17L | -61.53L | -78.7L | -1Cr | |||||
Comprehensive Income and Other | - | -2.96Cr | -2.96Cr | -2.95Cr | -2.93Cr | |||||
Total Common Equity | -8T | 9L | 26.4L | 15.07L | 82T | |||||
Total Equity | -8T | 9L | 26.4L | 15.07L | 82T | |||||
Total Liabilities And Equity | 10T | 11.55L | 27.85L | 16.93L | 5L | |||||
Supplemental Items | ||||||||||
ECS Total Shares Outstanding on Filing Date | 5L | 25Cr | 34Cr | 36Cr | 40Cr | |||||
ECS Total Common Shares Outstanding | 5L | 25Cr | 34Cr | 36Cr | 40Cr | |||||
Book Value / Share | -0.02 | 0 | 0.01 | 0 | 0 | |||||
Tangible Book Value | -8T | 7L | 6L | 15.07L | 82T | |||||
Tangible Book Value Per Share | -0.02 | 0 | 0 | 0 | 0 | |||||
Total Debt | 10T | 0 | 0 | 0 | 0 | |||||
Net Debt | 3T | -9L | -5L | -15.57L | -4L | |||||
Account Code - Inventory Valuation | - | 3 | 3 | 3 | 3 | |||||
Machinery, Total | - | - | - | - | - | |||||
Full Time Employees | - | 4 | 4 | 4 | 4 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















